Researchers supported by the IDG program will work with Nature Reviews Drug Discovery (NRDD) to develop new content on a regular basis highlighting understudied protein targets. Read the articles below to learn more about the IDG program and new proteins of interest.

• PKN3: a target in cancer metastasis
  September 14, 2022
   
• Novel drug targets in 2021
  March 31, 2022
   
• eEF2K: an atypical kinase target for cancer
  July 13, 2021
   
• PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disorders
  September 9, 2021
   
• BCKDK: an emerging kinase target for metabolic diseases and cancer
  June 11, 2021
   
• Novel drug targets in 2020
  April 6, 2021
   
• CDC42BPA/MRCKα: a kinase target for brain, ovarian and skin cancers
  February 8, 2021
   
• WNK kinases: an untapped opportunity to modulate ion transport
  November 6, 2020
   
• HCAR3: an underexplored metabolite sensor
  October 2, 2020
   
• STK19: a new target for NRAS-driven cancer
  June 25, 2020
   
• K_Na1.1 channels as a target for treating early-onset epilepsy
  May 13, 2020
   
• PIP5K1A: a potential target for cancers with KRAS or TP53 mutations
  April 24, 2020
   
• Novel drug targets in 2019
  April 9, 2020
   
• GPR84: An immune response dial?
  February 20, 2020
   
• PKMYT1: A forgotten member of the WEE1 family
  November 26, 2019
   
• ADCK3/COQ8a: The choice target of the UbiB protein kinase-like family
  September 16, 2019
   
• TRIC-B: an under-explored druggable ion channel
  July 26, 2019
   
• RIOK2:Straddling the kinase/ATPase line
  June 26, 2019
   
• CDK16: the pick of the understudied PCTAIRE kinases
  May 21, 2019
   
• Novel drug targets in 2018
  March 26, 2019